New trends in the treatment of bone metastasis

• Published in: Journal of cellular biochemistry 2007-12, Vol.102 (5), p.1095-1102
• Main Authors: Keller, Evan T., Dai, Jinlu, Escara-Wilke, June, Hall, Christopher L., Ignatoski, Kathleen, Taichman, Russell S., Keller, Jill
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - therapeutic use; BMP; Bone Neoplasms - drug therapy; Bone Neoplasms - pathology; Bone Neoplasms - secondary; breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; CXCR4; Diphosphonates - therapeutic use; Female; Humans; Male; Neoplasm Metastasis - drug therapy; Neoplasm Metastasis - pathology; Osteolysis - therapy; Osteoprotegerin - metabolism; prostate cancer; Prostatic Neoplasms - drug therapy; PTHrP; RANK Ligand - metabolism; RANKL; SDF; Wnt
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.21540

Bone metastasis is often the penultimate harbinger of death for many cancer patients. Bone metastases are often associated with fractures and severe pain resulting in decreased quality of life. Accordingly, effective therapies to inhibit the development or progression of bone metastases will have important clinical benefits. To achieve this goal understanding the mechanisms through which bone metastases develop and progress may provide targets to inhibit the metastases. In the past few years, there have been advances in both understanding the mechanisms through which bone metastases develop and how they impact bone remodeling. Additionally, gains in promising clinical strategies to target bone metastases have been developed. In this prospectus, we will discuss some of these advances. J. Cell. Biochem. 102: 1095–1102, 2007. © 2007 Wiley‐Liss, Inc.